BioXcel Therapeutics, Inc. (BTAI)
| Market Cap | 28.70M |
| Revenue (ttm) | 642,000 |
| Net Income (ttm) | -69.90M |
| Shares Out | 27.07M |
| EPS (ttm) | -5.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 491,272 |
| Open | 1.100 |
| Previous Close | 1.090 |
| Day's Range | 1.050 - 1.100 |
| 52-Week Range | 1.010 - 8.080 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+2,069.81%) |
| Earnings Date | May 8, 2026 |
About BTAI
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in... [Read more]
Full Company ProfileFinancial Performance
In 2025, BioXcel Therapeutics's revenue was $642,000, a decrease of -71.67% compared to the previous year's $2.27 million. Losses were -$69.90 million, 17.3% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 2,069.81% from the latest price.
News
BioXcel Therapeutics Transcript: Investor update
IGALMI is poised for a major market expansion as the first FDA-approved at-home treatment for acute agitation in bipolar and schizophrenia, with strong support from physicians, patients, and payers. Launch preparations target a Q1 2027 rollout, with ongoing efforts to secure payer access, educate prescribers, and explore partnerships.
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn.
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War ...
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outp...
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative m...
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative m...
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics Inc. (NASDAQ: BTAI) shares are down on Friday.
BioXcel Therapeutics Stock Rallies Opioid Study Success
BioXcel Therapeutics Inc. (NASDAQ: BTAI) shares are up during Thursday's premarket session following positive topline results from a Phase 2 study evaluating BXCL501 for treating opioid withdrawal sym...
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL...
BioXcel Therapeutics Transcript: Status update
Acute agitation in Alzheimer's dementia is a major unmet need, with current treatments relying on off-label sedatives that pose safety risks. BXCL501, a dexmedetomidine oral film, demonstrated rapid, well-tolerated efficacy in phase III trials and could significantly reduce caregiver burden and emergency visits.
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia
Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer's dementia Large patient population affected by Alzhei...
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI ® Submission timeline supports potential ap...
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary ...
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setti...
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines i...
BioXcel Therapeutics Transcript: AGM 2025
The meeting covered director elections, auditor ratification, executive compensation, and a precautionary reverse stock split proposal. All proposals passed, and questions addressed share sales and drug approval details. Final vote results will be published in a Form 8-K.
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs.
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease
NEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur...
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur...
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medic...
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neu...
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
BioXcel Therapeutics, Inc. BTAI on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects an...
BioXcel Therapeutics Transcript: Study Result
The SERENITY At-Home Phase III trial showed that dexmedetomidine sublingual film is safe, well-tolerated, and effective for self-administered treatment of acute agitation in patients with schizophrenia or bipolar disorder at home. Efficacy and safety were maintained with repeated use, supporting a planned supplemental NDA submission in 2026.